Background: Several ultrasound (US)-based risk stratification systems have been increasingly used for the optimal management of thyroid nodules. However, there are considerable discrepancies across these systems. This study aimed to summarize and compare the category-based diagnostic performance in the detection of thyroid cancer of different US-based risk stratification systems from four societies: the American College of Radiology-Thyroid Imaging Reporting and Data System (ACR-TIRADS), the American Thyroid Association (ATA), the Korean Thyroid Association/Korean Society of Thyroid Radiology (KTA/KSThR; K-TIRADS), and the European Thyroid Association (EU-TIRADS). Methods: MEDLINE/PubMed and EMBASE databases were searched to identify original articles investigating the category-based diagnostic performance according to at least one of the following guidelines: ACR-TIRADS, ATA, K-TIRADS, and EU-TIRADS. Pooled sensitivity and specificity were calculated using a bivariate random-effects model. A subgroup analysis on nodules of 1 cm or larger and a meta-regression analysis to identify factors associated with the diagnostic performance were performed. Results: A total of 29 articles including 33,748 thyroid nodules met the eligibility criteria and were included in the analysis. For ACR-TIRADS, the pooled sensitivity and specificity were, respectively, 66% and 91% for category 5 and 95% and 55% for category 4 or 5. For ATA, the pooled sensitivity and specificity were, respectively, 74% and 88% for category 5 and 91% and 64% for category 4 or 5. For K-TIRADS, the pooled sensitivity and specificity were, respectively, 55% and 95% for category 5 and 89% and 64% for category 4 or 5. For EU-TIRADS, the pooled sensitivity and specificity were, respectively, 82% and 90% for category 5 and 96% and 52% for category 4 or 5. Study location, proportion of female patients and malignant nodules, and study design were associated with study heterogeneity. Conclusions: The overall diagnostic performance of the four US-based risk stratification systems was comparable.
Thermal ablation is considered a novel treatment alternative for benign thyroid nodules, with one of the most promising techniques being radiofrequency ablation (RFA). Considering the increasing use of thyroid RFA, some societies have proposed these clinical practice guidelines. Therefore, we systemically reviewed these guidelines for thyroid RFA and compared the similarities and differences between them to identify a standard treatment strategy that has been agreed upon by most societies. We searched studies with human participants that were published in the English language from 1 January 2000 to 2 August 2019 using MEDLINE and EMBASE databases. Studies that included clinical practice guideline of benign thyroid RFA were included. We extracted data on the indication, pre- and post-procedural evaluation, techniques, and informed consent. Of 83 studies, 4 studies were included, and 1 study was added after searching the bibliographies of these articles. Five studies were guidelines developed by the Korean Society of Thyroid Radiology (KSThR), Italian scientific societies, Italian minimally invasive treatment of the thyroid, National Institute for Health and Care Excellence in the United Kingdom, and four professional Austrian thyroid associations. Indications, pre- and post-procedural evaluation, and techniques were similar; however, there were differences in each guideline for RFA of the thyroid gland. Major categories are similar in guidelines. Establishment of international thyroid RFA guidelines for benign thyroid nodules needs in the future.
Longer follow-up after radiofrequency ablation (RFA) of benign thyroid nodules is needed to understand regrowth and other causes of delayed surgery and long-term complications. This retrospective study included consecutive patients treated with RFA for symptomatic benign nonfunctioning thyroid nodules between March 2007 and December 2010. RFA was performed according to the standard protocol. We followed up patients at 1, 6, and 12 months, then yearly, until August 2022, and calculated the volume reduction ratio (VRR) at each follow-up. We assessed the incidence of regrowth according to three published criteria, delayed surgery, and complications. The Kaplan-Meier method was used to evaluate the cumulative incidence of regrowth, and univariable and multivariable Cox regression analyses were performed to identify risk factors for regrowth. This study included 421 patients (mean age, 47 ± 13 years; 372 women) with 456 nodules (mean volume, 21 ± 23 mL). The median follow-up period was 90 months (interquartile range, 24-143 months). The mean VRR was >80% at 2 years, 90% at 5 years, and 94% at ≥10 years. Overall regrowth was noted in 12% (53/456) of nodules and was treated with repeat RFA (n = 33) or surgery (n = 4), or left under observation (n = 16). Thyroid nodules with ≥20 mL initial volume had significantly higher risk of regrowth compared to nodules with <10 mL initial volume (hazard ratio, 2.315 [95% confidence interval, 1.183-4.530]; p = 0.014 on multivariable Cox regression analysis). Delayed surgery was performed in 6% (26/421) of patients because of regrowth and/or persistent symptoms (n = 4), or newly detected thyroid tumors (n = 22). The overall complication rate was 2.4% (10/421), with no procedure-related deaths or long-term complications. Radiofrequency ablation is safe and effective for treating benign thyroid nodules, with a high volume reduction ratio at long-term follow-up. Regular follow-up after initial success is warranted because of the possibility of regrowth of ablated nodules and the need for delayed surgery in some patients.